Article Sidebar

Submitted
November 27, 2025
Published
October 29, 2025
Download
PDF
Statistic
Read Counter : 9 Download : 3

Main Article Content

Abstract

Recently, there has been evidence that semaglutide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA) approved for type 2 diabetes and obesity, may help lower alcohol intake and cravings. Modification of several neurobiological systems that control reward, motivation, and stress reactions is the pharmacological basis for this effect. By inhibiting mesolimbic dopamine signalling, central GLP-1 receptor activation, specifically in the ventral tegmental area (VTA), nucleus accumbens (NAc), prefrontal cortex, amygdala, and hypothalamus, reduces the reinforcing effects of alcohol. Additionally, semaglutide increases satiety and decreases the motivational salience of alcohol cues by activating the gut–brain axis through vagal afferents. GLP-1R stimulation may also lessen neuroinflammatory processes linked to long-term alcohol exposure and restore normaly to the dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis. Semaglutide and related GLP-1R agonists may be promising pharmacotherapeutic candidates for alcohol use disorder (AUD) because these mechanisms work together to suppress alcohol reward, craving, and stress-induced relapse.        

Article Details

How to Cite
THE ROLE OF GLP-1RECEPTOR AGONIST IN MODULATING ALCOHOL INTAKE: INSIDES FROM SEMAGLTIDE THERAPY. (2025). International Journal of Research in Pharmacology & Pharmacotherapeutics, 14(4), 759-775. https://doi.org/10.61096/ijrpp.v14.iss4.2025.759-775
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

How to Cite

THE ROLE OF GLP-1RECEPTOR AGONIST IN MODULATING ALCOHOL INTAKE: INSIDES FROM SEMAGLTIDE THERAPY. (2025). International Journal of Research in Pharmacology & Pharmacotherapeutics, 14(4), 759-775. https://doi.org/10.61096/ijrpp.v14.iss4.2025.759-775

References

  1. 1. Farokhnia M, Tazare J, Pince CL, et al. Glucagon-like peptide-1 receptor agonists, but not dipeptidyl peptidase-4 inhibitors, reduce alcohol intake in humans and preclinical models. J Clin Invest. 2025;135(9):e192414.
  2. 2. Marty VN, Farokhnia M, Munier S, Mulpuri RS, Leggio L, Spigelman I. Long-acting glucagon-like peptide-1 receptor agonists suppress voluntary alcohol intake in male Wistar rats. Alcohol. 2020;87:71-82. PubMed
  3. 3. Aranäs L, … (et al.). Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male vervet monkeys. Psychopharmacology. 2023; (details). PubMed
  4. 4. Systematic review: “A systematic review on the role of glucagon-like peptide-1 receptor agonists on alcohol-related behaviours: potential therapeutic strategy for alcohol use disorder.” Addict Behav. 2024; (in press) –summarises animal and human evidence of GLP-1RA effects on alcohol consumption.
  5. 5. Novak U, Wilks A, Buell G, McEwen S. Identical mRNA for preproglucagon inpancreas and gut. Eur J Biochem. 1987;164(3):553‐558.
  6. 6. Alvarez E, Roncero I, Chowen JA, Thorens B, Blázquez E. Expression of theglucagon-like peptide-1 receptor gene in rat brain. J Neurochem. 1996;66(3):920‐927.
  7. 7. Boileau I., Assaad J.M., Pihl R.O., et al. Alcohol promotes dopamine release in the human nucleus accumbens. Synapse. 2003;49(4):226–231. doi: 10.1002/syn.10226. [DOI] [PubMed] [Google Scholar]
  8. 8. Engel J.A., Fahlke C., Hulthe P., et al. Biochemical and behavioral evidence for an interaction between ethanol and calcium channel antagonists. J Neural Transm. 1988;74(3):181–193. doi: 10.1007/BF01244784. [DOI] [PubMed] [Google Scholar
  9. 9. Imperato A., Di Chiara G. Preferential stimulation of dopamine release in the nucleus accumbens of freely moving rats by ethanol. J Pharmacol Exp Ther. 1986;239(1):219–228. [PubMed] [Google Scholar]
  10. 10. Blomqvist O., Soderpalm B., Engel J.A. Ethanol-induced locomotor activity: involvement of central nicotinic acetylcholine receptors? Brain Res Bull. 1992;29(2):173–178. doi: 10.1016/0361-9230(92)90023-q. [DOI] [PubMed] [Google Scholar]
  11. 11. Di Michele S., Ericson M., Sillén U., Engel J.A., Söderpalm B. The role of catecholamines in desmopressin induced locomotor stimulation. J Neural Transm. 1998;105(10-12):1103–1115. doi: 10.1007/s007020050115. [DOI] [PubMed] [Google Scholar
  12. 12. Engel J., Strombom U., Svensson T.H., Waldeck B. Suppression by alpha-methyltyrosine of ethanol-induced locomotor stimulation: partial reversal by L-dopa. Psychopharmacologia. 1974;37(3):275–279. doi: 10.1007/BF00421541. [DOI] [PubMed] [Google Scholar]
  13. 13. Jayaram-Lindström N., Ericson M., Steensland P., Jerlhag E. In: Recent advances in drug addiction research and clinical applications. Meil W., editor. IntechOpen; 2016. Dopamine and alcohol dependence: from bench to clinic; pp. 81–114. [DOI] [Google Scholar]
  14. 14. King A., Vena A., Hasin D.S., deWit H., O'Connor S.J., Cao D. Subjective responses to alcohol in the development and maintenance of alcohol use disorder. Am J Psychiatry. 2021;178(6):560–571. doi: 10.1176/appi.ajp.2020.20030247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. 15. Heilig M., Egli M. Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. PharmacolTher. 2006;111(3):855–876. doi: 10.1016/j.pharmthera.2006.02.001. [DOI] [PubMed] [Google Scholar]
  16. 16. Jerlhag E. 2018. GLP-1 signaling and alcohol-mediated behaviors preclinical and clinical evidence; pp. 343–349. [DOI] [PubMed] [Google Scholar]
  17. 17. Jerlhag E. Gut-brain axis and addictive disorders: a review with focus on alcohol and drugs of abuse. PharmacolTher. 2019;196:1–14. doi: 10.1016/j.pharmthera.2018.11.005. [DOI] [PubMed] [Google Scholar]
  18. 18. Suchankova P., Yan J., Schwandt M.L., et al. The glucagon-like peptide-1 receptor as a potential treatment target in alcohol use disorder: evidence from human genetic association studies and a mouse model of alcohol dependence. Transl Psychiatry. 2015;5(6):e583. doi: 10.1038/tp.2015.68. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. 19. Vallöf D., Maccioni P., Colombo G., et al. The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents. Addict Biol. 2016;21(2):422–437. doi: 10.1111/adb.12295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. 20. Egecioglu E., Steensland P., Fredriksson I., Feltmann K., Engel J., Jerlhag E. The glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodents. Psychoneuroendocrinology. 2013;38(8):1259–1270. doi: 10.1016/j.psyneuen.2012.11.009. [DOI] [PubMed] [Google Scholar]
  21. 21. Vallöf D., Kalafateli A.L., Jerlhag E. Long-term treatment with a glucagon-like peptide-1 receptor agonist reduces ethanol intake in male and female rats. Transl Psychiatry. 2020;10(1):238. doi: 10.1038/s41398-020-00923-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. 22. Sørensen G., Caine S.B., Thomsen M. Effects of the GLP-1 agonist exendin-4 on intravenous ethanol self-administration in mice. Alcohol Clin Exp Res. 2016;40(10):2247–2252. doi: 10.1111/acer.13199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. 23. Klausen M.K., Thomsen M., Wortwein G., Fink-Jensen A. The role of glucagon-like peptide 1 (GLP-1) in addictive disorders. Br J Pharmacol. 2022;179(4):625–641. doi: 10.1111/bph.15677. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. 24. Nauck M.A., Quast D.R., Wefers J., Meier J.J. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021;46 doi: 10.1016/j.molmet.2020.101102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. 25. Wilding J.P.H., Batterham R.L., Calanna S., et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. doi: 10.1056/NEJMoa2032183. [DOI] [PubMed] [Google Scholar]
  26. 26. Bucheit J.D., Pamulapati L.G., Carter N., Malloy K., Dixon D.L., Sisson E.M. Oral semaglutide: a review of the first oral glucagon-like peptide 1 receptor agonist. Diabetes TechnolTher. 2020;22(1):10–18. doi: 10.1089/dia.2019.0185. [DOI] [PubMed] [Google Scholar]
  27. 27. Marty V.N., Farokhnia M., Munier J.J., Mulpuri Y., Leggio L., Spigelman I. Long-acting glucagon-like peptide-1 receptor agonists suppress voluntary alcohol intake in male Wistar rats. Front Neurosci. 2020;14 doi: 10.3389/fnins.2020.599646. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. 28. Costa V.D., Tran V.L., Turchi J., Averbeck B.B. Dopamine modulates novelty seeking behavior during decision making. BehavNeurosci. 2014;128(5):556–566. doi: 10.1037/a0037128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. 29. Deyoung C.G. The neuromodulator of exploration: a unifying theory of the role of dopamine in personality. Front Hum Neurosci. 2013;7:762. doi: 10.3389/fnhum.2013.00762. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. 30. Simms J.A., Steensland P., Medina B., et al. Intermittent access to 20% ethanol induces high ethanol consumption in long-evans and Wistar rats. Alcohol Clin Exp Res. 2008;32(10):1816–1823. doi: 10.1111/j.1530-0277.2008.00753.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. 31. Sirohi S., Schurdak J.D., Seeley R.J., Benoit S.C., Davis J.F. Central & peripheral glucagon-like peptide-1 receptor signaling differentially regulate addictive behaviors. PhysiolBehav. 2016;161:140–144. doi: 10.1016/j.physbeh.2016.04.013. [DOI] [PubMed] [Google Scholar]
  32. 32. Thomsen M., Dencker D., Wortwein G., et al. The glucagon-like peptide 1 receptor agonist Exendin-4 decreases relapse-like drinking in socially housed mice. PharmacolBiochemBehav. 2017;160:14–20. doi: 10.1016/j.pbb.2017.07.014. [DOI] [PubMed] [Google Scholar]
  33. 33. Thomsen M., Holst J.J., Molander A., Linnet K., Ptito M., Fink-Jensen A. Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys. Psychopharmacology (Berl) 2019;236(2):603–611. doi: 10.1007/s00213-018-5089-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. 34. Jerlhag E., Egecioglu E., Landgren S., et al. Requirement of central ghrelin signaling for alcohol reward. Proc Natl Acad Sci U S A. 2009;106(27):11318–11323. doi: 10.1073/pnas.0812809106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. 35. Vallöf D., Kalafateli A.L., Jerlhag E. Brain region specific glucagon-like peptide-1 receptors regulate alcohol-induced behaviors in rodents. Psychoneuroendocrinology. 2019;103:284–295. doi: 10.1016/j.psyneuen.2019.02.006. [DOI] [PubMed] [Google Scholar]
  36. 36. Kalafateli A.L., Satir T.M., Vallof D., Zetterberg H., Jerlhag E. An amylin and calcitonin receptor agonist modulates alcohol behaviours by acting on reward-related areas in the brain. Prog Neurobiol. 2021;200 doi: 10.1016/j.pneurobio.2020.101969. [DOI] [PubMed] [Google Scholar]
  37. 37. Kalafateli A.L., Vallof D., Jerlhag E. Activation of amylin receptors attenuates alcohol-mediated behaviours in rodents. Addict Biol. 2019;24(3):388–402. doi: 10.1111/adb.12603. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. 38. Jensen L., Helleberg H., Roffel A., et al. Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species. Eur J Pharm Sci. 2017;104:31–41. doi: 10.1016/j.ejps.2017.03.020. [DOI] [PubMed] [Google Scholar]
  39. 39. Gabery S., Salinas C.G., Paulsen S.J., et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020;5(6) doi: 10.1172/jci.insight.133429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. 40. Kalafateli A.L., Vallöf D., Colombo G., Lorrai I., Maccioni P., Jerlhag E. An amylin analogue attenuates alcohol-related behaviours in various animal models of alcohol use disorder. Neuropsychopharmacology. 2019;44(6):1093–1102. doi: 10.1038/s41386-019-0323-x. [DOI] [PMC free article] [PubMed] [Google Scholar]